This is default featured slide 1 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 2 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 3 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 4 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 5 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

Alkem Laboratories appoints Amrut Naik as CEO

Alkem Laboratories announced the appointment of Amrut Naik as its new Chief Executive Officer. His appointment is effective from November 11, following board approval and nomination committee recommendations. Naik has more than 26 years of experience in various areas, including pharmaceuticals and biologics. He holds both a bachelor's and master's degree in pharmaceutical science alongside a PhD in pharmacology.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Qhj5Lzp
via IFTTT

High Court restrains NPPA from action against AstraZeneca

The Delhi High Court has issued a temporary restraining order against the NPPA's actions toward AstraZeneca Pharma. This order remains in effect until the next hearing date, January 11. AstraZeneca has argued that its product may not fall under controlled drug prices. The NPPA has accused AstraZeneca of overcharging for the inhaler from May 2016 to November 2025. AstraZeneca denies these allegations and claims compliance with the price regulations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/91SKhc4
via IFTTT

Wockhardt expands novel antibiotic Miqnaf's access; Q2 revenue rises 24%

Wockhardt has expanded its marketing access for Miqnaf in India following the removal of a supply condition. The company's biotechnology sector recorded significant revenue growth, indicating strong demand for its products. Zaynich received US FDA approval for complicated urinary tract infections, serving as a milestone for Indian pharmaceuticals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hyKNisU
via IFTTT

Experts say health technology, preventive healthcare at inflection point, India ready to leverage

With a focus on preventive healthcare and wellness, India is on the verge of harnessing new technological innovations. Sangita Reddy from Apollo Hospitals stresses the significance of wearable devices in spotting health issues early on. In collaboration with Apollo Hospitals, Garmin Health is targeting rural health efforts and highlighting the event's health technology strides.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1BwDgi8
via IFTTT

India’s medicine sales grow in double digits for four straight quarters, led by chronic care drugs

Over the past four quarters, India's medicine sales have increased significantly due to rising demand in chronic care segments. The growth rate reached 12% year-on-year in the September quarter, showing a positive trend in the industry. Larger pharmaceutical companies have benefited from the shutdown of many non-compliant smaller units. Budgets were also boosted by a reduction in GST on medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ztCd01h
via IFTTT

India's first public sector proton beam therapy unit to come up in Assam; state signs MoU with Belgian firm

Assam has signed an MoU with Belgium-based Ion Beam Applications (IBA) to set up India's first public-sector proton beam therapy centre in Guwahati at a cost of Rs 600 crore. The facility will offer advanced cancer treatment, particularly for children, and is expected to take at least three years to become operational.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8QGNRKm
via IFTTT

Cancer drug prices fell in 2019 too, but mark-ups of up to 700% are back

The government's latest cancer drug price cuts may offer patients some relief, but the impact could be short-lived. An analysis of medicines covered in the 2019 exercise found that mark-ups had risen to as much as 700% by 2026, raising questions about whether one-time price cuts can keep cancer treatment affordable.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lV5JvIn
via IFTTT